Silvant Capital Management LLC Has $4.45 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Silvant Capital Management LLC grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 18.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 16,195 shares of the biopharmaceutical company's stock after buying an additional 2,534 shares during the period. Silvant Capital Management LLC's holdings in Alnylam Pharmaceuticals were worth $4,454,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Plato Investment Management Ltd lifted its holdings in Alnylam Pharmaceuticals by 2,666.3% during the first quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company's stock worth $674,000 after acquiring an additional 4,346 shares in the last quarter. Diversified Trust Co bought a new position in Alnylam Pharmaceuticals during the second quarter worth about $1,210,000. Headlands Technologies LLC bought a new position in Alnylam Pharmaceuticals during the first quarter worth about $471,000. Breakwater Capital Group bought a new position in Alnylam Pharmaceuticals during the second quarter worth about $249,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Alnylam Pharmaceuticals by 5.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company's stock worth $550,837,000 after acquiring an additional 201,784 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on ALNY shares. Barclays boosted their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a report on Friday. HC Wainwright restated a "buy" rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, October 18th. Raymond James boosted their price target on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an "outperform" rating in a report on Friday. Cantor Fitzgerald restated a "neutral" rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. Finally, Citigroup boosted their price target on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a "buy" rating in a report on Friday, August 2nd. Six analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $294.50.

Alnylam Pharmaceuticals Stock Up 2.7 %

Shares of Alnylam Pharmaceuticals stock traded up $7.32 on Friday, hitting $273.91. The stock had a trading volume of 866,294 shares, compared to its average volume of 871,240. The stock has a market cap of $35.16 billion, a price-to-earnings ratio of -104.55 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The business's 50 day moving average is $274.61 and its two-hundred day moving average is $225.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. The business's revenue was up 107.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($2.21) earnings per share. As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.59 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Dennis A. Ausiello sold 20,250 shares of the business's stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the transaction, the director now directly owns 136 shares in the company, valued at approximately $35,632. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Yvonne Greenstreet sold 15,000 shares of the firm's stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the sale, the chief executive officer now directly owns 73,441 shares of the company's stock, valued at $20,563,480. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Dennis A. Ausiello sold 20,250 shares of the business's stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now directly owns 136 shares of the company's stock, valued at approximately $35,632. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.